The primary role of this medication is to provide supportive assistance in managing conditions where temporary, focused circulatory support is relevant when supportive symptomatic management is appropriate.

Restoration of Functional Erection

This domain addresses the symptomatic pattern of impaired erectile function in adult men, where the ability to achieve or sustain penile firmness for successful sexual intercourse is compromised. It is commonly used for conditions characterized by episodic or fluctuating manifestations, such as erectile dysfunction of vascular, neurogenic, or mixed etiology, and is also applied as an adjunctive aid in diagnosis. The core benefit provided may assist with maintaining functional stability, contributing to improved comfort, enhanced intimacy, and overall patient satisfaction. Patients seeking this therapy often experience symptoms that interfere with daily functioning, as the medication contributes to the management of these specific functional deficits.

---

Urgent Management of Critical Neonatal Circulation

Alprostadil Panpharma is also applied in urgent situations involving critical circulatory compromise in newborn infants. This is relevant in conditions where symptoms of systemic imbalance and organ-specific functional stress require intervention relevant to the urgent nature of the symptoms to help maintain essential blood flow. For these neonates, the therapeutic benefit provides supportive relief during a critical period of temporary physiological imbalance, which supports general well-being and assists medical teams with the time needed to plan and execute definitive procedures to address the condition.

---

Quick Fact: Supportive Role in Functional Stability This medication is relevant across two distinct clinical areas: providing episodic functional support for adult men experiencing impaired erectile function and offering temporary circulatory support in critically ill newborn infants.

Regulatory References

1. NIH MedlinePlus Drug Information

Alprostadil Panpharma is for use in adult men and is contraindicated for several specific populations and clinical conditions, as defined in official regulatory documents.

---

Contraindicated Populations

The medicine must not be used by men who have:

• A known hypersensitivity or allergy to alprostadil or any other component in the formulation.
• Conditions that predispose them to priapism (a prolonged erection), such as sickle cell anemia or trait, multiple myeloma, or leukemia.
• Anatomical defects of the penis, including severe angulation, cavernosal fibrosis, or Peyronie's disease.
• Penile implants.
• Underlying medical conditions, particularly unstable cardiovascular disorders, for which sexual activity is generally considered medically inadvisable or contraindicated.

---

Eligibility-Related Rules

The medicine is not indicated for use in women, children, or neonates. Additionally, if the patient develops signs of penile angulation, cavernosal fibrosis, or Peyronie's disease during treatment, use must be discontinued.

The interaction profile for Alprostadil Panpharma is primarily defined by pharmacodynamic effects stemming from its action as a potent vasodilator. Regulatory documentation explicitly states interaction patterns based on additive effects on circulation and blood clotting.

Pharmacodynamic Interaction Restrictions

Co-administration is officially classified as restricted or not recommended with other agents used for erectile dysfunction, including Phosphodiesterase-5 (PDE5) Inhibitors (such as sildenafil or tadalafil) and other vasoactive agents (such as phentolamine or papaverine). This restriction is in place due to the risk of additive effects, including potentiated systemic hypotension and the risk of priapism (prolonged erection).

Potentiation of Systemic Effects

Combining Alprostadil with systemic antihypertensive drugs or other generalized vasoactive medications increases the officially documented risk for hypotension. This particular pharmacodynamic interaction requires consideration in populations such as elderly patients, who may experience an increased susceptibility to low blood pressure. Furthermore, concurrent use with anticoagulants or platelet aggregation inhibitors increases the officially noted propensity for localized bleeding at the administration site.

Other Interaction Considerations

The regulatory labels note that sympathomimetics and certain decongestants may functionally oppose Alprostadil’s action, potentially reducing its overall effect. Pharmacokinetic (PK) interactions, such as those mediated by CYP enzymes or drug transporters, are generally considered unlikely in official documentation due to the drug’s rapid local metabolism and clearance. No formal interactions with food, alcohol, or herbal products are established in the regulatory labels for local formulations.

Molecular Agonism and cAMP Activation

The foundational mechanism involves Alprostadil acting as an agonist at specific E-type Prostanoid receptors ( EP2, EP3, EP4) on the vascular smooth muscle. This molecular interaction immediately stimulates the enzyme Adenylate Cyclase ( AC), triggering the second-messenger pathway by rapidly increasing the intracellular concentration of cyclic AMP ( cAMP).

---

Ca^2+ Modulation and Smooth Muscle Relaxation

The subsequent surge in cAMP acts as the biochemical signal to reduce the availability of intracellular calcium ( Ca^2+). Since high Ca^2+ levels are necessary for muscle contraction, this cAMP-mediated modulation inhibits the contractile process, resulting in the rapid relaxation of the localized smooth muscle tissue.

---

Vascular Tone and Regional Perfusion

The resulting relaxation of the arterial and sinusoidal smooth muscle immediately reduces vascular resistance, causing localized vasodilation. This fundamental physiological change leads to a sustained increase in regional blood flow and local tissue perfusion, which is the observable physiological consequence of the drug’s molecular mechanism.

Alprostadil Panpharma is administered via distinct methods and dosing schedules, which are strictly dictated by the clinical context of use. The initial use of all formulations must be established and supervised by a healthcare professional, ensuring the lowest effective dose is determined through titration.

Administration Scope

Feature	Details for Adult Localized Use (Erectile Dysfunction)	Details for Neonatal Systemic Use (Cardiac Management)
Route of Administration	Intracavernosal Injection, Intraurethral Insertion, or Topical Application (formulation-dependent).	Continuous Intravenous (IV) Infusion.
Dosing Schedule	Titrated Dosing: Initial injection doses start from 1.25 mcg to 2.5 mcg; subsequent increases are incremental until a satisfactory, non-prolonged response is achieved. Doses should not exceed 60 mcg (injection) or 1000 mcg (intraurethral).	Weight-based Dosing: Initial infusion rate is typically 0.05 to 0.1 mcg/kg/minute. The maintenance rate must be reduced to the lowest possible dosage that maintains the desired effect.
Frequency & Limits	As-Needed Basis: Must be used no more than once per day and no more than three times per week, with at least 24 hours between uses.	Short-Term/Continuous Infusion: Administered continuously until definitive medical intervention or resolution.

Special Procedural Conditions

• Preparation: Lyophilized powder for injection must be reconstituted with the supplied diluent before use. The concentrate for IV infusion must be diluted (e.g., with normal saline or dextrose) to the required concentration prior to administration.
• Supervision: The first dose and titration process must be completed in a physician’s office to confirm the correct technique and monitor the response, particularly ensuring the duration of the effect does not exceed one hour.
• Neonatal Context: The IV infusion must be delivered via a constant rate pump and into a large vein or umbilical artery catheter, with solutions prepared fresh every 24 hours.

Recent Clinical Evidence for Alprostadil

Alprostadil, a synthetic form of prostaglandin E1, is a long-established local pharmacotherapy for erectile dysfunction (ED). Clinical research consistently focuses on its efficacy, safety profile, and role as a second-line treatment, particularly for men who do not respond to or cannot use oral phosphodiesterase type-5 (PDE5) inhibitors.

Efficacy and Outcomes in Clinical Trials

Randomized controlled trials (RCTs) have primarily investigated the intracavernosal (injection) and intraurethral (suppository) routes of administration. These studies evaluate the ability to achieve and maintain an erection adequate for sexual intercourse.

Administration Route	Key Efficacy Findings
Intracavernosal	Reported effective at restoring the ability to participate in intercourse in up to 70% of men with ED, and around 85% in those who failed oral therapy.
Intraurethral	Demonstrated a statistically significant improvement in ED symptoms compared to placebo in meta-analyses. Response rates are typically lower than with injection therapy.

Safety and Tolerability

Overall, the use of alprostadil is associated with localized, mild-to-moderate side effects. Because the drug acts locally, systemic adverse events are generally uncommon.

• Common Localized Effects: Pain at the injection or application site, penile pain, and penile erythema (redness) are the most frequently reported adverse events in clinical study populations.
• Serious Risks: The main serious risk identified across trials is priapism (an erection lasting longer than four hours), which occurred in a small percentage of patients (typically less than 5%). Trial data also reported the occurrence of penile fibrosis (scarring) in a minority of patients.

Clinical evidence confirms alprostadil's role as an important therapeutic option, with long-term studies providing data on its sustained use and management of potential complications.

Common questions about Alprostadil Panpharma (FAQ)

Q: What is Alprostadil Panpharma used for?

Alprostadil Panpharma is used to treat erectile dysfunction (impotence) in men. Erectile dysfunction is the inability to achieve or maintain a firm erection suitable for sexual activity. The medication contains alprostadil, which is a form of a naturally occurring substance that helps widen blood vessels, allowing blood to flow more easily into the penis to produce an erection.

Q: How does Alprostadil Panpharma work?

Alprostadil is a prostaglandin, a type of naturally occurring chemical compound in the body. When used as a treatment, it works by relaxing the smooth muscles and widening the blood vessels within the penis. This increased blood flow helps to trap blood in the erectile tissues, which is necessary to achieve and maintain an erection.

Q: What should I tell my doctor before using Alprostadil Panpharma?

It is important to inform your doctor about your full medical history and all other medications you are currently taking. Specifically, you should discuss:

• Any history of conditions that may cause a long-lasting erection (priapism), such as sickle cell anemia, multiple myeloma, or leukemia.
• Any existing problems with the shape or structure of your penis (such as Peyronie’s disease or angulation).
• Any active infection or inflammation of the penis.
• If you are taking any blood thinners (anticoagulants), as this may increase the risk of bleeding.
• If you have a history of low blood pressure (hypotension) or heart disease.

Q: What are the common side effects of Alprostadil Panpharma?

Some common side effects that may occur with the use of Alprostadil Panpharma include:

• Pain or soreness at the application site or in the penis.
• Redness, itching, or a rash on the genitals.
• Dizziness or light-headedness, especially when standing up.
• A prolonged erection lasting more than 4 hours (priapism), which requires immediate medical attention.

If you experience any severe side effects or an erection that lasts longer than 4 hours, seek urgent medical care.

Q: Can Alprostadil Panpharma be used if I am taking blood thinners?

If you are taking medications to prevent blood clots (blood thinners or anticoagulants), you must inform your doctor. Using Alprostadil Panpharma alongside these medications may increase the risk of bleeding or finding blood in the urine. Your doctor will assess the risks and determine if this treatment is appropriate for you.

The storage and disposal of Alprostadil formulations must strictly follow the requirements defined in regulatory labeling to maintain stability and ensure safe handling.

Storage Requirements

Product State	Temperature and Conditions
Unreconstituted Powder	Store at or below 25 C (77 F), or at Controlled Room Temperature, and protect from light and moisture.
Reconstituted Solution	Must be used immediately (single use). Do not freeze. Do not refrigerate. May be stored for a maximum of 24 hours at or below 25 C if not used immediately.

Disposal and Safety

All components must be kept out of the sight and reach of children. The medicine should remain in its original container prior to use.

Used needles and syringes must be placed immediately into a puncture-resistant sharps disposal container. Unused or expired medicine must be discarded according to local pharmaceutical waste regulations; the product must not be disposed of via household trash or wastewater.